Precision oncology startup 4baseCare has partnered with Caritas Hospitals in Kottayam to integrate advanced genomic testing and data-driven insights into routine cancer care, enabling targeted therapies and better outcomes for patients in Kerala and surrounding areas.
Glimpse:
4baseCare and Caritas Hospitals have launched a collaboration to deliver personalized, genomics-guided cancer treatment in Kottayam, Kerala. Doctors at Caritas can now leverage 4baseCare’s genetic testing tools including comprehensive genomic profiling (CGP), ctDNA liquid biopsy, and germline testing to analyze each patient’s unique cancer biology. This enables more precise, effective treatments with reduced side effects, bridging advanced diagnostics with clinical practice and expanding access to modern oncology in the region. The partnership strengthens patient-centric care through real-world clinico-genomic data and supports 4baseCare’s mission to serve underrepresented populations.
A major step forward in regional cancer care has been taken as precision oncology startup 4baseCare joins forces with Caritas Hospitals, a prominent multispeciality facility in Kottayam, Kerala. The partnership introduces cutting-edge genomic technologies directly into hospital-based clinical practice, allowing oncologists to gain detailed insights into the molecular profile of individual tumors and tailor treatments accordingly.
Under the agreement, Caritas Hospitals now offers advanced services such as comprehensive genomic profiling (CGP), circulating tumor DNA (ctDNA) liquid biopsy, and germline testing through the newly established Caritas-4baseCare Centre. These tools help identify actionable mutations and biomarkers, guiding the selection of targeted therapies and immunotherapies that match the patient’s specific cancer biology often resulting in higher efficacy and fewer adverse effects compared to traditional one-size-fits-all approaches.
The collaboration addresses key challenges in cancer care for Kerala and nearby regions, where access to sophisticated genomic diagnostics has historically been limited. By embedding precision oncology within a trusted hospital setting, the initiative reduces the need for patients to travel long distances for specialized testing and ensures faster, more informed clinical decisions. It also contributes to building population-relevant clinico-genomic datasets from Indian patients, helping improve treatment strategies for underrepresented groups.
This move aligns with 4baseCare’s broader expansion strategy, following its recent INR 90 crore Series B funding round. The company is actively growing its network of hospital-linked genomics labs across India and internationally, including the Middle East, Southeast Asia, Latin America, and Central Asia. The Kerala partnership marks a significant milestone in making AI-powered precision oncology more accessible and integrated into everyday cancer management.
“This partnership with 4baseCare strengthens our ability to offer patients truly personalized cancer care, guided by science, driven by data, and delivered with empathy. By integrating advanced genomics into everyday clinical practice, we are not only improving treatment precision but also expanding access to modern cancer care for patients across the region.”
By
HB Team
